Key result
CKD after nonkidney organ transplantation is linked to ~4.6-fold higher mortality.
Answers are grounded in this paper and cite their sources.
Outlines clinical management of chronic kidney disease after nonkidney solid organ transplantation, highlighting calcineurin inhibitor toxicity and metabolic complications.
Introduction Because survival has improved after heart, lung, and liver transplantation, progressive loss of kidney function is increasingly common. In a registry study of nearly 70,000 recipients of nonkidney solid organ transplant (NKSOT), development of CKD, defined as GFR≤29 ml/min per 1.73 m2, was associated with a 4.55 (95% CI: 4.38–4.74; P<0.001) relative risk of death (1). Risk factors for CKD vary slightly between organs but generally include age, pretransplant kidney function, type of organ transplanted, AKI, exposure to calcineurin inhibitors (CNIs), hypertension, diabetes, and hepatitis C (1,2). Because the prevalence of CKD among NKSOT recipients increases, many of these patients will be cared for by general nephrologists. The practice of evaluating and managing these complex patients is often extrapolated from guidelines developed for the general CKD population (3) or the management of kidney transplant recipients (4). We present two patients to illustrate key elements of diagnostic and therapeutic decision making regarding the care of NKSOT recipients with CKD. Patient 1 A 66-year-old woman who underwent bilateral lung transplantation 4 years ago is referred with a serum creatinine of 2.1 mg/dl. Her perioperative course was complicated by AKI requiring hemodialysis. There were multiple early episodes of rejection necessitating higher doses of tacrolimus. Serum creatinine has slowly risen over the last 2–3 years. BP is 150/92 mm Hg, and examination is unremarkable. Laboratory data include hemoglobin 8.7 g/dl, CO2 17 mEq/L, tacrolimus level 9.5 ng/ml, transferrin saturation 17%, and ferritin 422 ng/ml. Urinalysis is bland with trace proteinuria. Dual energy x-ray absorptiometry scan reveals osteoporosis in the hip and spine. Assessment of CKD after NKSOT CKD is common after NKSOT (1,2), and in our experience, it is often under-recognized in its early stages. In patients with lung transplants, creatinine-based methods often underestimate the rate of GFR loss and/or do not detect small losses in GFR. A systematic evaluation of creatinine-based GFR estimations in NKSOT recipients identified that the CKD Epidemiology Collaboration equation, which performs better at higher GFRs, and the four-variable Modification of Diet in Renal Disease study (MDRD) study equation, more accurate at lower GFRs, were preferred (5). Using the MDRD equation, our patient has an eGFR of 24 ml/min. The differential diagnosis of CKD after NKSOT is influenced by the presence of immunosuppression and the circumstances surrounding the primary transplant. In a single-center series of 105 biopsies performed in recipients of nonkidney transplants, sequelae of hypertension and CNI toxicity were common, but patients with glomerular disease and thrombotic microangiopathy were also identified (6). We recommend considering kidney biopsy in the following situations: rapid or unexplained decline in kidney function, active urine sediment, and nephrotic-range proteinuria. For most patients, we recommend quantification of proteinuria and assessment for plasma cell dyscrasias with a combination of serum and urine electrophoresis and serum free light-chain testing. We would not biopsy this patient, because her presentation is consistent with chronic CNI toxicity superimposed on early AKI. Chronic CNI toxicity is a disease of progressive interstitial fibrosis characterized by a bland urinalysis with minimal proteinuria. Although the relationship between exposure and kidney toxicity is not linear, higher levels of CNIs over longer periods of time generally lead to higher rates of CKD (1,2). Management of CKD after NKSOT Hypertension is common after NKSOT, and many patients require combination therapy to control BP. We suggest that early aggressive BP control is important and recommend targets as outlined by the Joint National Commission VIII on the basis of age and degree of proteinuria (7). Renin-angiotensin-aldosterone system (RAAS) blockade can be challenging in this population because of hemodynamic effects, hyperkalemia, and anemia. Data are inconclusive regarding efficacy and safety of RAAS blockers in patients with kidney transplants. In this elderly patient who does not have diabetes or significant proteinuria, we would target a BP of <140/90 mm Hg. On the basis of efficacy, tolerability, and minimal drug-drug interactions, our first choice would be a dihydropyridine calcium channel blocker. A β-blocker or combined αβ-blocker is a reasonable alternative. Many transplant-related factors, including medications, chronic inflammation, and infection, can contribute to anemia, which is often disproportionate to the level of CKD in recipients of NKSOT. In our experience, many of these patients, especially those with concomitant pulmonary or cardiac dysfunction, feel better at the higher end of the recommended hemoglobin target range of 10–11.5 g/dl (3,4). In this patient, we would initiate epoetin and intravenous iron to maintain iron saturation >20%. We would also assess for blood loss and other causes of erythropoetin resistance. The risk of bone disease and fracture is increased in transplant recipients because of the use of immunosuppression (particularly corticosteroids), nutritional compromise, low vitamin D levels, and frailty. Concomitant CKD complicates matters. In patients with stages 4 and 5 CKD, dual energy x-ray absorptiometry scanning is controversial, because it does not predict fracture risk, particularly of the hip and spine (4). Furthermore, bone mineral density does not predict the type of bone disease in kidney transplant recipients (8). Vitamin D deficiency should be corrected (4). Prednisone doses should be kept to the lowest level that remains protective. The role of denosumab, which is not cleared through the kidney and may be beneficial in patients with GFR of 15–30 ml/min, in this population is unclear. This patient’s bone disease is likely multifactorial, and the challenge is differentiating between osteoporosis and the other components of CKD metabolic bone disease. We recommend checking biochemical markers of bone turnover, including serum calcium, 25-hydroxy vitamin D, intact parathyroid hormone, and alkaline phosphatase. The objective is to treat hyperparathyroidism using vitamin D analogs, calcimimetics, and phosphate binders (3) but not oversuppress intact parathyroid hormone. We generally avoid the use of bisphosphonates in patients with GFR<30 ml/min. In the case of fragility fracture or if other causes of CKD metabolic bone disease have been ruled out, a GFR-adjusted dose of bisphosphonate may be indicated, but it carries risk for low-turnover bone disease. We also aggressively treat acidosis with bicarbonate supplementation to maintain a TCO2 of at least 23 mEq/L. Recommended vaccine coverage includes influenza, pertussis, pneumococcal-13, and pneumococcal-23. We stress hepatitis B immunity, especially for those who may require RRT. Live vaccines, including varicella, are contraindicated. Planning for Kidney Replacement Therapy in the NKSOT Recipient Dialysis in the NKSOT recipient can be complex, and we recommend early dialysis modality training using home modalities when feasible and involving the primary transplant team in modality and access planning. We advocate for early referral for kidney transplantation evaluation in recipients of NKSOT with CKD. The benefits and ethics of kidney after lung transplantation have been debated. Studies have shown a survival benefit for transplant versus remaining on the waitlist, but outcomes are inferior to those of standard kidney transplant recipients (1,9). We recommend an individualized approach and when possible, encourage use of a live donor. Obtaining a 24-hour urine averaged urea and creatinine clearance measurement may reveal a GFR≤20 ml/min, allowing for immediate transplant listing. Patient 2 A 45-year-old man with hepatitis C cirrhosis underwent liver transplant 1 year ago and is referred for hyperkalemia and hypomagnesemia. On initial presentation, BP is 155/90 mm Hg, and there is no peripheral edema. Laboratory data include potassium 5.3 mmol/L, magnesium 1.3 mg/dl, and serum creatinine 1.7 mg/dl. Medications include tacrolimus, fludrocortisone, and metoprolol. Electrolyte Abnormalities after Liver Transplantation Hyperkalemia is common after liver transplant, and it is often secondary to CNIs, which suppress the RAAS, increase chloride reabsorption, and suppress Na+-K+ ATPase function. Hyperkalemia is often managed with fludrocortisone, and we favor this approach for patients with low or normal BP and without significant edema. In patients who are hypertensive, we recommend thiazide diuretics, and in patients with significant edema or significant CKD, twice daily loop diuretics can be used. In this patient, we would encourage a low-potassium diet and discontinue fludrocortisone in favor of chlorthalidone. In select patients, we use potassium binding resins but are mindful of timing of dosing, because they can interfere with immunosuppression absorption. Urinary magnesium wasting is a common side effect of CNIs and may be exacerbated by diuretics. Long-term oral magnesium replacement and/or the use of amiloride in the patient who is not hyperkalemic are often necessary. Patient 2 Revisited In response to the presence of ongoing kidney dysfunction, this patient was transitioned from tacrolimus to sirolimus 18 months after transplant. He is referred 1 year later with increasing creatinine and proteinuria. Examination reveals significant lower extremity edema. Laboratory data include hemoglobin 8.5 g/dl, serum creatinine 2.3 mg/dl, total cholesterol 290 mg/dl, and urine protein-to-creatinine ratio 2.2 g/g. Minimizing CNI exposure after NKSOT is an important objective. Many have suggested that early conversion from CNIs to mammalian target of rapamycin inhibitors, particularly everolimus, is associated with improved preservation of kidney function after liver transplant. However, in patients with advanced CKD, mammalian target of rapamycin inhibitors are often poorly tolerated, and kidney outcomes are worse in cases of established proteinuria (10). This patient is potentially exhibiting many of the adverse effects of sirolimus, including edema, proteinuria, anemia, and hyperlipidemia. In this patient, we recommend asking the transplant team to transition back to tacrolimus. The differential diagnosis for this patient’s proteinuria is broad. Without significant improvement in proteinuria after discontinuation of sirolimus, we would proceed with biopsy. Disclosures None.
No takes yet. Share an insight, caveat, or question.
Warburton et al. (2018) conducted a review in Chronic kidney disease in nonkidney solid organ transplant recipients (n=2). Evaluation and management strategies for post-transplant CKD (calcineurin inhibitor adjustment, BP control, electrolyte management) was evaluated. Chronic kidney disease after nonkidney solid organ transplantation is associated with an increased relative risk of death.
Synapse has enriched 10 related papers. Consider them for comparative context: